Cambrex Milan Celebrates 80 Years with New $30 Million R&D Center
Cambrex, a leading organization in contract development and manufacturing (CDMO), is celebrating a significant milestone with the announcement of a new research and development (R&D) center at its Milan facility. This landmark $30 million investment is set to boost Cambrex's capabilities in advanced analytical development and process research, while also modernizing several of its production sites.
The expansion project is slated for completion in the second half of 2027, positioning Cambrex to better meet the increasing demands for CDMO services. To further ensure growth and innovation, the company has also acquired adjacent land at its Milan site. This strategic acquisition provides the necessary capacity for future technological advancements and operational expansion.
This year, Cambrex Profarmico in Milan proudly commemorates its 80th anniversary, reflecting on its rich history of supporting the development and production of pharmaceutical products for an international clientele. Recent celebrations included a gathering of the Milan team, which highlighted eight decades of scientific achievements and commitment to human health.
Claudio Russolo, the Chief Operating Officer at Cambrex, expressed his enthusiasm for the new facility, stating, "The initiation of this new facility represents the enduring legacy and expertise of our Milan team. For 80 years, this site has been a pillar in the pharmaceutical sector in Europe. With this expansion, we are investing not only in new technologies and skills but also in the future of our employees and partners."
This substantial investment builds on Cambrex’s reputation for scientific excellence and industrial leadership, preparing the organization for a new phase of growth. By enhancing its R&D capabilities in Milan, Cambrex strengthens its ability to address the increasing complexity of today's small-molecule therapeutics.
Cambrex has made a name for itself as one of the leading global CDMO organizations, providing a full spectrum of services for the development and manufacturing of active pharmaceutical ingredients throughout the drug lifecycle. With over 45 years of expertise and a dedicated team of 2,000 professionals supporting clients across North America and Europe, Cambrex offers a wide array of specialized technologies in drug substance development. These include continuous manufacturing, controlled substances, peptide synthesis, solid-state science, biocatalysis, materials characterization, synthesis of complex compounds, and highly potent active pharmaceutical ingredients (HPAPI).
The new R&D center is expected to enhance Cambrex's ability to formulate innovative solutions in the pharmaceutical landscape, supporting the growing demand for intricate small-molecule products. This initiative not only aims to secure the company's future but also to uphold its commitment to advancing healthcare outcomes globally.
In conclusion, Cambrex's investment in Milan marks a pivotal step forward, celebrating 80 years of history while looking towards a future filled with potential advancements in pharmaceutical sciences. This is a testimony to Cambrex's ongoing commitment to innovation, quality, and the betterment of health worldwide.
As the project progresses, Cambrex is poised to continue making strides in the pharmaceutical industry, ensuring that it remains at the forefront of development and manufacturing capabilities.
The expansion project is slated for completion in the second half of 2027, positioning Cambrex to better meet the increasing demands for CDMO services. To further ensure growth and innovation, the company has also acquired adjacent land at its Milan site. This strategic acquisition provides the necessary capacity for future technological advancements and operational expansion.
This year, Cambrex Profarmico in Milan proudly commemorates its 80th anniversary, reflecting on its rich history of supporting the development and production of pharmaceutical products for an international clientele. Recent celebrations included a gathering of the Milan team, which highlighted eight decades of scientific achievements and commitment to human health.
Claudio Russolo, the Chief Operating Officer at Cambrex, expressed his enthusiasm for the new facility, stating, "The initiation of this new facility represents the enduring legacy and expertise of our Milan team. For 80 years, this site has been a pillar in the pharmaceutical sector in Europe. With this expansion, we are investing not only in new technologies and skills but also in the future of our employees and partners."
This substantial investment builds on Cambrex’s reputation for scientific excellence and industrial leadership, preparing the organization for a new phase of growth. By enhancing its R&D capabilities in Milan, Cambrex strengthens its ability to address the increasing complexity of today's small-molecule therapeutics.
Cambrex has made a name for itself as one of the leading global CDMO organizations, providing a full spectrum of services for the development and manufacturing of active pharmaceutical ingredients throughout the drug lifecycle. With over 45 years of expertise and a dedicated team of 2,000 professionals supporting clients across North America and Europe, Cambrex offers a wide array of specialized technologies in drug substance development. These include continuous manufacturing, controlled substances, peptide synthesis, solid-state science, biocatalysis, materials characterization, synthesis of complex compounds, and highly potent active pharmaceutical ingredients (HPAPI).
The new R&D center is expected to enhance Cambrex's ability to formulate innovative solutions in the pharmaceutical landscape, supporting the growing demand for intricate small-molecule products. This initiative not only aims to secure the company's future but also to uphold its commitment to advancing healthcare outcomes globally.
In conclusion, Cambrex's investment in Milan marks a pivotal step forward, celebrating 80 years of history while looking towards a future filled with potential advancements in pharmaceutical sciences. This is a testimony to Cambrex's ongoing commitment to innovation, quality, and the betterment of health worldwide.
As the project progresses, Cambrex is poised to continue making strides in the pharmaceutical industry, ensuring that it remains at the forefront of development and manufacturing capabilities.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.